Publications by authors named "Shaun Chandna"

Background: The natural history of primary sclerosing cholangitis (PSC) among African Americans (AA) is not well understood.

Methods: Transplant-free survival and hepatic decompensation-free survival were assessed using a retrospective research registry from 16 centers throughout North America. Patients with PSC alive without liver transplantation after 2008 were included.

View Article and Find Full Text PDF

Liver biopsy is essential for management in liver transplant patients with clinical features suspicious for acute cellular rejection (ACR). As more patients are transplanted for noninfectious indications, it has become increasingly common for them to receive treatment for presumed ACR before biopsy. The effect of pretreatment on the classic histologic triad of ACR's mixed portal inflammation, endothelialitis, and bile duct damage is not well described.

View Article and Find Full Text PDF

Patients with cirrhosis account for 3% of intensive care unit admissions with hospital mortality exceeding 50%; however, improvements in survival among patients with acutely decompensated cirrhosis and organ failure have been described when treated in specialized liver transplant centers. Acute-on-chronic liver failure is a distinct clinical syndrome characterized by decompensated cirrhosis associated with one or more organ failures resulting in a significantly higher short-term mortality. In this review, we will discuss the management of common life-threatening complications in the patient with cirrhosis that require intensive care management including neurologic, cardiovascular, gastrointestinal, pulmonary, and renal complications.

View Article and Find Full Text PDF

Background And Aims: Gastric antral vascular ectasia (GAVE) is typically treated by endoscopic thermal therapies. Endoscopic band ligation (EBL) has been reported in the treatment of GAVE with encouraging results. However, EBL is not widely used to this end.

View Article and Find Full Text PDF

Background & Aims: Hepatocellular carcinoma (HCC) surveillance rates are suboptimal in clinical practice. We aimed to elicit providers' opinions on the following aspects of HCC surveillance: preferred strategies, barriers and facilitators, and the impact of a patient's HCC risk on the choice of surveillance modality.

Methods: We conducted a web-based survey among gastroenterology and hepatology providers (40% faculty physicians, 21% advanced practice providers, 39% fellow-trainees) from 26 US medical centers in 17 states.

View Article and Find Full Text PDF
Article Synopsis
  • The study investigates how U.S. hepatology practitioners view and manage the use of direct-acting antivirals (DAAs) for patients with hepatitis C who also have hepatocellular carcinoma (HCC), despite differences in opinions regarding HCC recurrence risks following DAA treatment.
  • Out of 476 surveyed providers, a majority believe that DAAs are beneficial for patients who have successfully been treated for HCC, recommending them for early-stage patients, but less so for those with intermediate or advanced HCC.
  • There is a notable variation in when providers prefer to start DAA therapy after HCC treatments, with many suggesting initiation within three months post-surgery or procedure, while others advocate for
View Article and Find Full Text PDF